ClinicalTrials.gg
Status unknownNCT05027373Updated Aug 30, 2021

Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection

A Phase 1 interventional study of SSGJ-613 and Placebo in Systemic Juvenile Idiopathic Arthritis and Periodic Fever Syndrome, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-30.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Arthritis, Juvenile with a site in China — 10 open to participants now, 10 under way, 4 of them phase 3. Arthritis, Juvenile · China.

Planned enrollment
12th of 14
34 · median 83
Started
2021
with 1 other
Phase 1
4 of 20
1 open now
Registered
9th of 20
by date

Among the 20 studies in Arthritis, Juvenile with a site in China, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 9th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

10 of the 20 studies in Arthritis, Juvenile with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arthritis, Juvenile with a site in China, or all of them as a file.
02

Study summary

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled parallel trial of safety, tolerability and pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody by single subcutaneous injection with five different doses in healthy subjects. There are 5 groups as follows: 0.03mg/kg (S1), 1.0mg/kg (S2), 3.0mg/kg (S3), 6.0mg/kg (S4) and 10.0mg/kg (S5); and 2 subjects were included in the S1 group (both received study drugs); 8 subjects were included in each of the S2 \~ S5 groups (of which 6 received study drugs and 2 received placebo). In each group, two subjects were sentinels (1 received the study drug and 1 placebo). Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.

03

Conditions studied

  • Systemic Juvenile Idiopathic Arthritis
  • Periodic Fever Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese healthy participants, male or female, aged 18 to 45 (including both ends)
  • The (BMI) is in the range of 19.0\~28.0 kg•m-2 (including both ends), and the weight of men is generally not less than 50kg, while the women is generally not less than 45kg
  • Male participants and their partners or female participants must agree to take one or more non-drug (such as complete abstinence, contraceptive rings, partner ligation, etc.) , and there is no sperm donation or egg donation plan until 3 months after finished the study
  • Participants should fully understand the purpose, nature, methods and possible adverse reactions of the trial, volunteer to participate in the trial and sign the
  • Participants could communicate well with the researchers and compliance with the trial

Exclusion criteria

Exclusion Criteria:

  • Those who are allergic to the study drug and any of its . Subjects who have a history of allergy to monoclonal antibodies
  • Subjects who have or are currently suffering from any serious clinical diseases 3-6 months before screening, such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities or any other that can interfere with the study results
  • Clinical laboratory examinations (blood routine, urine routine, blood biochemistry, coagulation function, etc.), auxiliary examinations (chest X-ray, abdominal ultrasound) found to be abnormal and have clinical significance
  • Positive for surface antigen (HBsAg), hepatitis B core antibody (HbcAb), anti- virus antibodies (HCV), or anti- (HIV)
  • Alcoholics or frequent drinkers within 3 months before the trial, drinking more than 14 units per week (1 unit alcohol ≈360 mL beer or 45 mL spirits or 150 mL wine), or those who have a positive alcohol breath test (screening period or baseline period) or couldn't prohibit alcohol during the trial
  • Those who smoked more than 5 cigarettes per day during the 3 months before screening, or have a positive urine nicotine screening test (screening period or baseline period)
  • Drug abusers or those who have used soft drugs (such as marijuana) within 3 months or took hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the trial, or have positive drug abuse screening (morphine, Ketamine, tetrahydrocannabinol acid, methamphetamine , dimethyldioxyamphetamine, cocaine)
  • Has taken any prescription medicine, non-prescription medicine, Chinese patent medicine within 14 days before administration
  • Has received any monoclonal antibody drugs within 3 months before administration
  • Has a history of vaccination within 3 months before dosing, or intend to receive vaccines during the study
  • Was previously enrolled in other clinical trials within 3 months before dosing
  • Blood donors or subjects who lost a lot of blood (> 400 mL, except for women's physiological period) or those who received blood transfusion or used blood products within 3 months
  • Can't tolerate venipuncture or has a history of halo needles and halo blood
  • Has known or suspected pregnancy or lactation
  • Abnormal vital signs (SBP \<90 mmHg or ≥140 mmHg, DBP \<55 mmHg or ≥90 mmHg; heart rate \<50 bpm or> 100 bpm; body temperature \<35.4℃ or > 37.3℃) or abnormal ( ≥450 ms) or physical examination are (according to the judgment of clinical research doctors)
  • Those who are infected and need to be treated for acute or chronic infections, as follows:

    • Suffering from herpes zoster within 12 months before screening;
    • Currently in any inhibitory treatment for chronic infections (eg, tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster virus, and atypical mycobacteria);
    • A history of tuberculosis or contact with patients with open tuberculosis in the past 6 months,or a T-spoT-positive results;
    • Infected with parasites within 3 months before administration;
    • Hospitalized for infectious diseases within 30 days before administration;
    • Received anti-infective drugs (including antibacterial, antiviral, antifungal, or antiparasitic drugs) by parenteral administration (iv or im) 30 days before administration
  • Subjects who are unsuited to the study for any reason, judged by the investigators
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    SSGJ-613

    Drug: SSGJ-613

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.

  • DrugPlacebo

    Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: up to 112 days

  2. Tmax

    Time frame: up to 112 days

  3. AUC0-t

    Time frame: up to 112 days

  4. t1/2

    Time frame: up to 112 days

  5. CL/F

    Time frame: up to 112 days

  6. Vd/F

    Time frame: up to 112 days

  7. Ke

    Time frame: up to 112 days

  8. AUC0-∞

    Time frame: up to 112 days

  9. AE

    Time frame: up to 112 days

  10. SAE

    Time frame: up to 112 days

Secondary outcomes

  1. total IL-1β

    Time frame: up to 112 days

  2. free IL-1β

    Time frame: up to 112 days

  3. ADA

    Bridging method will be used to detect the incidence and titer for ADA through one three-step detection strategy, that is preliminary screening, confirmation and titer

    Time frame: up to 112 days

07

Study locations

1 of 1 sites recruiting
  • Shanghai Xuhui District Central Hospital
    Shanghai, Shanghai 201203, China
    Recruiting
    • Chuan Lu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Apr 2022, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2021
First posted
Aug 30, 2021
StartActual
Aug 13, 2021
Primary completionEst.
Apr 30, 2022
CompletionEst.
Sep 30, 2022
Last update
Aug 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05027373
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Aug 13, 2021
Primary completion
Apr 30, 2022 (estimated)
Completion
Sep 30, 2022 (estimated)
Last update
Aug 30, 2021

Study contacts

Qian Chen, PhD
Contact
qchen@shxh-centerlab.com
02154030254

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SSGJ-613

Start the discussion